< Back to the Blog

About the author

Amy Divaraniya
Dr. Aparna (Amy) Divaraniya is the Founder and CEO of Oova. She has over 10 years experience working in data science and a PhD in Biomedical Sciences. In 2017, Amy pivoted to women's healthcare after facing her own fertility struggles. Amy started Oova to give women control over their fertility by making high-quality hormone testing more accessible.

Sources

  1. Leiva and colleagues on timing urinary PdG relative to ultrasound ovulation. 2026. Metabolite timing and limits of extrapolation to serum.
  2. Monitoring the menstrual cycle through urinary and serum reproductive hormones. 2015. Prospective comparison with ultrasound in 40 normally menstruating women.
  3. ASRM fertility evaluation committee opinion. Progesterone timing and limits of single measurements.
  4. Ecochard and colleagues on urinary PdG to confirm ovulation. 2013. Observational analysis using ultrasound and urinary measurements; not product-specific Oova validation.
  5. Ovarian Monitor research on PdG, BBT, and cervical mucus and research on hydration and urinary PdG. Urine sampling context; hydration study population was early pregnancy.
  6. ASRM luteal phase deficiency committee opinion. Diagnostic limitations.
  7. Urinary progesterone and pregnanediol during progesterone treatment. Primary study of treatment effects on urinary and serum measurements.

About the Oova Blog:
‍Our content is developed with a commitment to high editorial standards and reliability. We prioritize referencing reputable sources and sharing where our insights come from. The Oova Blog is intended for informational purposes only and is never a substitute for professional medical advice. Always consult a healthcare provider before making any health decisions.